局限期小细胞肺癌三维适形放疗及同步化疗的临床研究

目的 观察三维适形放疗(3DCRT)同步化疗对局限期小细胞肺癌(LSCLC)的疗效及毒副反应.方法 93例LSCLC患者随机分为3DCRT组(46例)和常规组(47例),均先顺铂+足叶乙甙或卡铂+足叶乙甙方案化疗1周期,再同步放化疗,然后继续化疗,共4-6周期.达完全缓解者给予脑预防照射30 Gy分10次.常规组按常规设野,3DCRT组只包括原发灶、转移淋巴结及邻近一站淋巴引流区.放疗2 Gy/次,5次/周,共60～64 Gy.结果 3DCRT组和常规组随访率分别为100%和100%,随访时间满1、2、3年者分别为36和34、16和14、7和8例.3DCRT组和常规组完全缓解率分别为52%和47%,有效率分别为89%和85%(χ~2=0.34,P=0.759).3DCRT组和常规组1、2,3年生存率分别为78%和72%、35%和30%、15%和17%(χ~2=0.18,P=0.92),中位生存期分别为23.2和22.8个月.三维适形放疗组1+2级早期放射性肺和食管反应、1+2、3级晚期放射性肺损伤均轻于常规放疗组,两组均无3、4级早期肺和食管反应,以及4级晚期肺损伤;1+2、3、4级急性骨髓抑制两组相似.结论 3DCRT同步化疗用于LSCLC治疗可获得满意的近、远期疗效,毒副反应小,有较高的临床可行性.

Clinical outcomes of concurrent three-dimensional conformal radiotherapy and chemotherapy for limited-stage small cell lung cancer

Objective To evaluate therapeutic effects and complications of concurrent three-dimensional conformal radiotherapy (3DCRT) and chemotherapy in patients with limited-stage small cell lung cancer (LSCLC).Methods From June 2000 to August 2005, 93 histologically proved LSCLC patients were randomized into two groups:3DCRT group (n =46) and conventional group (n =47).In both groups, patients received one cycle chemotherapy, followed by concurrent chemoradiotherapy and then received consolidate chemotherapy.Chemotherapy was four to six cycles of PE regimen.Conventional irradiation field was setup in conventional group, while in 3 DCRT group clinical target volume (CTV) only involved visible tumor and adjacent lymphatic region.Radiotherapy was delivered at 2 Gy per fraction, 5 fractions per week to a median total dose of 60 -64 Gy.Those who achieved a complete response were treated with prophylactic cranial irradiation (PCI) with 30 Gy in 10 fractions.Results The follow-up rate was 100% in both groups.The number of patients completed 1-, 2-and 3-year follow-up were 36, 34 and 16 in 3DCRT group, 14, 7 and 8 in conventional group, respectively.The complete and overall response rate were 52% and 89% in 3DCRT group, while 47% and 85% in conventional group, respectively.The 1-, 2-and 3-year survival rates were 78%, 35% and 15% in 3DCRT group, 72%, 30% and 17% in conventional group, respectively.The median survival time was 23.2 and 22.8 months, respectively.There was no statistical difference in short-term (Χ~2 = 0.34 ,P = O.759) and long-term outcomes (Χ~2 = 0.18 ,P = 0.92).In 3DCRT group, the incidence of grade 1 +2 acute radiation pneumonitis and esophagitis, grade 1 +2 and grade 3 chronic radiation pneumonitis were lower than those in conventional group.There was no grade 3 or 4 acute radiation pneumonitis or esophagitis, or grade 4 chronic radiation pneumonitis in both groups.There was no difference in grade 1 + 2, grade 3 or grade 4 acute myelo-suppression between the two groups.Conclusions In the treatment of LSCLC, concurrent 3DCRT and chemotherapy can achieve satisfactory short-term and long-term outcomes with acceptable complications.